Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)

12 november 2026 uppdaterad av: GlaxoSmithKline

A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

700

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF).
  • Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion Criteria:

  • Has symptomatic central nervous system (CNS) metastases, CNS metastases with hemorrhagic features, or leptomeningeal disease.
  • Has known allergy or hypersensitivity to study intervention components or excipients.
  • Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose steroids or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
  • Has moderate to severe pulmonary disease or current clinically significant pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
  • Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
  • Known active infectious diseases requiring systemic treatment or known human immunodeficiency virus (HIV).
  • Has received any prior systemic anticancer treatment for the disease under study.
  • Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
  • Has severe, uncontrolled, or active cardiovascular disorders.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Ris-Rez + atezolizumab

Ris-Rez will be administered.

Atezolizumab will be administered.

Aktiv komparator: Etoposide, carboplatin, atezolizumab ± lurbinectedin

Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin.

Carboplatin will be administered.

Atezolizumab will be administered.

Etoposide will be administered.

Lurbinectedin will be administered.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall survival (OS)
Tidsram: Up to 50 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to 50 months
Progression-free survival (PFS) by Blinded independent central review (BICR) assessment
Tidsram: Up to 50 months

PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first.

Up to 50 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to confirmed deterioration of disease-related symptoms and physical functioning
Tidsram: Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured.

Up to 63 months
Brain PFS
Tidsram: Up to 63 months

Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline.

Up to 63 months
PFS by Investigator Assessment
Tidsram: Up to 63 months

PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.

Up to 63 months
Objective response rate (ORR)
Tidsram: Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment.

Up to 63 months
Duration of response (DOR)
Tidsram: Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
ORR for participants not receiving bridging cycle
Tidsram: Up to 63 months

ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment

Up to 63 months
DOR for participants not receiving bridging cycle
Tidsram: Up to 63 months

DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

Up to 63 months
Participant reported experience on study treatment
Tidsram: Up to 63 months

Number of participants who reported their experience with study treatment using validated questionnaires will be measured.

Up to 63 months
Time to worsening of participants overall quality of life
Tidsram: Up to 63 months

Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured.

Up to 63 months
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity
Tidsram: Up to 63 months
Up to 63 months
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Tidsram: Up to 63 months
Up to 63 months
Number of participants with changes in hematology parameters
Tidsram: Up to 63 months
Up to 63 months
Observed pharmacokinetic concentration of Ris-Rez
Tidsram: Up to 63 months
Up to 63 months
Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez
Tidsram: Up to 63 months
Up to 63 months
Titres of ADA against Ris-Rez
Tidsram: Up to 63 months
Up to 63 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: GSK Clinical Trials, GlaxoSmithKline

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

25 december 2026

Primärt slutförande (Beräknad)

24 februari 2031

Avslutad studie (Beräknad)

24 mars 2032

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Tidsram för IPD-delning

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Kriterier för IPD Sharing Access

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera